Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
Standard
Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. / Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.
in: HUM VACC IMMUNOTHER, Jahrgang 15, Nr. 10, 2019, S. 2269-2285.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
AU - Fathi, Anahita
AU - Dahlke, Christine
AU - Addo, Marylyn M
N1 - Letter
PY - 2019
Y1 - 2019
N2 - The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/ ). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens.
AB - The devastating Ebola virus (EBOV) outbreak in West Africa in 2013-2016 has flagged the need for the timely development of vaccines for high-threat pathogens. To be better prepared for new epidemics, the WHO has compiled a list of priority pathogens that are likely to cause future outbreaks and for which R&D efforts are, therefore, paramount (R&D Blueprint: https://www.who.int/blueprint/priority-diseases/en/ ). To this end, the detailed characterization of vaccine platforms is needed. The vesicular stomatitis virus (VSV) has been established as a robust vaccine vector backbone for infectious diseases for well over a decade. The recent clinical trials testing the vaccine candidate VSV-EBOV against EBOV disease now have added a substantial amount of clinical data and suggest VSV to be an ideal vaccine vector candidate for outbreak pathogens. In this review, we discuss insights gained from the clinical VSV-EBOV vaccine trials as well as from animal studies investigating vaccine candidates for Blueprint pathogens.
KW - Clinical Trials as Topic
KW - Communicable Diseases, Emerging/prevention & control
KW - Ebola Vaccines/immunology
KW - Genetic Vectors
KW - Hemorrhagic Fever, Ebola/prevention & control
KW - Humans
KW - Vaccines, Attenuated
KW - Vesiculovirus
KW - Viral Proteins/immunology
KW - Viral Vaccines/immunology
KW - Virus Diseases/prevention & control
KW - World Health Organization
U2 - 10.1080/21645515.2019.1649532
DO - 10.1080/21645515.2019.1649532
M3 - SCORING: Review article
C2 - 31368826
VL - 15
SP - 2269
EP - 2285
JO - HUM VACC IMMUNOTHER
JF - HUM VACC IMMUNOTHER
SN - 2164-5515
IS - 10
ER -